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“The Commission presents the EU’s Pharmaceutical 
Strategy: a paradigm shift?” 
 
 
Sabrina Röttger-Wirtz1 
 
 
Presenting a Pharmaceutical Strategy for Europe 
in the middle of a pandemic has moved the 
European Commission into the spotlight in an 
area that otherwise is probably more of a niche 
topic in the EU law and policy community. Still, 
it should be clarified that the Pharmaceutical 
Strategy is not a reaction to the COVID-19 crisis: 
many of the action points contained in the 
Strategy can be traced back to the mission letter 
that President von der Leyen provided 
Commissioner Kyriakides with in September 
2019. However, while reforms of the regulatory 
framework were to be expected, the COVID-19 
pandemic has certainly been a catalyst for the 
Commission initiatives in this area. 
The key action points of the Pharmaceutical 
Strategy are not surprising for those that have 
followed the debates in EU pharmaceutical law 
and policy in the recent years. To summarise the 
areas of concern: accessibility of medicines; 
antimicrobial resistance (AMR); pharmaceutical 
industry competitiveness and innovation 
facilitation; regulatory efficiency; supply chain 
dependence; and environmental risks. These 
topics were also raised in the 2017 European 
Parliament Resolution on options for improving 
access to medicines and the 2018 European 
Parliament Resolution on Antimicrobial 
Resistance. 
The first challenge identified in the Strategy is 
accessibility to medicine, and the Commission 
has identified several aspects that require 
improvement. First of all, the Commission made 
clear that it sees the need to foster and steer 
innovation in areas of currently unmet medical 
need – this refers to the lack of medicines for 
certain rare diseases as well as neglected patient 
groups like children, senior citizens and pregnant 
or breastfeeding women. This also became 
evident in the evaluation of the respective legal 
measures currently in place, as published in 
August. Without regulatory interference there is 
little economic incentive to develop these 
products and the currently existing incentives 
have been successful only in certain therapeutic 
areas. An Inception Impact Assessment has 
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already been published for the revision.  
Additionally, a problem of the current regulatory 
framework is that medicines, even though they 
obtained EU-wide marketing authorisations, are 
not accessible in all Member States because 
companies may choose not to market their 
product in certain countries. Here, the 
Commission considers making incentives 
conditional on improved accessibility. 
Other accessibility problems concern the current 
debate surrounding excessive pricing of 
pharmaceuticals.  The competence for 
pharmaceutical pricing as an important 
component of the organisation of national 
healthcare systems lies with the Member States. 
Therefore, the Commission in the Pharmaceutical 
Strategy mostly focusses on strengthening 
cooperation between the Member States and also 
aims to make the cost of medicines development 
more transparent. It also wants to use public 
procurement practices and the enforcement of 
competition law to address this issue. Finally, the 
Strategy in this context refers to the already 
proposed Health Technology Assessments 
(HTA) Regulation, which first met resistance in 
the Council of the European Union but now 
seems to have been reinvigorated by the 
pandemic, and aims to strengthen the cooperation 
of the Member States in establishing the added 
value of a new medicine. 
One issue that was already recognised before the 
pandemic, but which has been magnified by 
COVID-19, is medicines shortages due to 
interruptions in the supply chain. Europe is 
currently highly dependent on the production of 
medicines and their active ingredients in third-
countries and this has already led to shortages in 
the past. The Commission in the Strategy 
announced that a study to assess the causes of 
shortages is underway and that the legislative 
framework could potentially be reviewed in order 
to place more responsibilities on the industry to 
ensure stable supply. In this regard, the Strategy 
is not as pronounced as some might have 
expected in moving pharmaceutical production 
back to Europe. 
Along with these more patient-centred 
accessibility issues, the Commission also wants 
to support innovation and competitiveness of the 
EU pharmaceutical industry. In this regard, the 
vision of the Strategy is very focussed on 
digitalisation and the creation of the European 
Health Data Space to be established until 2025. 
Furthermore, taking into account  the Intellectual 
Property Action Plan, the supplementary 
protection certificate system will be streamlined. 
Main areas of innovation like gene and cell 
therapies, personalised medicines and medicines 
containing or consisting of GMOs should be 
supported through revising the regulatory 
frameworks for innovative clinical trials and the 
use of real-world data in the assessment process. 
Overall, the strategy in terms of the regulatory 
procedures in place does not propose radical 
changes, but more the increasing of regulatory 
flexibility in the face of technological and 
scientific progress. 
Finally, the strategy promises actions with regard 
to the global threat of antimicrobial resistance, 
environmental risks caused by pharmaceutical 
production and disposal, as well as maintaining a 
strong European position in global regulatory 
cooperation. Thus overall, the Strategy contains 
few surprises and it is also not the start of a 
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revolutionary overhaul of the regulation of 
pharmaceuticals in the EU. This is a testament to 
the efficiency of the framework in place. 
However, the Pharmaceutical Strategy does 
address existing problems for patients by 
promising to fine-tune incentive structures and 
revise regulatory approaches to benefit from new 
technologies. The Strategy has been welcomed by 
the European Parliament, however, the 
announced reassessment of the incentive schemes 
has raised criticism in the industry. 
From a more general EU law perspective the 
Pharmaceutical Strategy is interesting, as it 
indicates a shift from a pharmaceutical policy that 
is driven by the facilitation of the free movement 
of goods and strongly emphasised the regulation 
of risks with regard to medicinal products, to 
questions of accessibility of the products for 
patients and the steering of innovation via 
incentive schemes. This is not to say that the EU 
was not active in these areas before, as the 
Regulations for orphan medicinal products and 
paediatrics or the proposed HTA Regulation 
show. However, it is remarkable how little 
internal market and risk regulation concerns 
feature in the Strategy and how pronounced the 
new patient-centred approach is presented. 
The legal basis for the adoption of EU legislation 
in the field of pharmaceuticals is to be found in 
the internal market provision of Article 114 
TFEU, sometimes in conjunction with Article 
168(4) TFEU providing for the adoption of 
‘(m)easures setting high standards of quality and 
safety for medicinal products and devices for 
medical use’. This is to be contrasted with the 
organisation of health care systems which 
remains the competence of the Member States, as 
enshrined in Article 168(7) TFEU. The focus on 
accessibility in the Strategy and the rethinking of 
incentives to steer innovation is thus by no means 
self-evident and the Commission is also careful to 
emphasise that in many planned initiatives that 
the EU action will be limited to supporting 
Member State cooperation. Similar competence 
questions are raised in the debate surrounding the 
European Health Union. However, where the 
Pharmaceutical Strategy is indeed seen as a first 
step towards the reorientation of the focus of 
pharmaceutical policy, it is a paradigm shift and 
maybe even an indicator of a maturing of the 
regulatory framework. 
With regard to the Pharmaceutical Strategy a key 
question will be whether and in how far this 
reorientation will receive the support of the 
Member States. Just to put the re-gained 
enthusiasm for EU health competences into 
context, in 2017 the European Commission in its 
White Paper on the future of Europe in one 
presented scenario had included public health as 
an area where the EU ‘is perceived as having 
more limited added value, or as being unable to 
deliver on promises’. Looking at the history of 
market integration for pharmaceuticals and also 
the resistance that the HTA Regulation proposal 
has met in the Council before the pandemic, 
health law in general and pharmaceutical law in 
particular are politically and economically 
sensitive areas for the Member States.  The 
question where competences regarding medicines 
accessibility and pricing should be allocated is 
complex. However, it is clear that the issues that 
the Commission raises in the Pharmaceutical 
Strategy are far more connected to the 
organisation of the healthcare systems of the 
Member States than the traditional market and 
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risk policy in the pharmaceutical sector. In the 
State of the Union Address, President von der 
Leyen has said that: ‘it is clearer than ever that we 
must discuss the question of health competences.’ 
Therefore, the progress of the initiatives proposed 
in the Pharmaceutical Strategy might provide 
some insights into the prospect of the Unions 
repositioning in health law in general. 
 
Dr. Sabrina Röttger-Wirtz is an Assistant 
Professor of EU Law at the Maastricht Centre for 
European Law (Maastricht University), working 
on EU risk regulation in the fields of 
pharmaceuticals, foods and pesticides.  
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